Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program

Submitted by Emmanuel Lemoine on Thu, 03/26/2015 - 14:26

Titre: Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program

Type de publication: Article de revue

Auteur: Lieu, Christopher H [1], Renfro, Lindsay A [2], de Gramont, Aimery [3], Meyers, Jeffrey P [4], Maughan, Timothy S [5], Seymour, Matthew T [6], Saltz, Leonard [7], Goldberg, Richard M [8], Sargent, Daniel J [9], S. Eckhardt, Gail [10], Eng, Cathy [11]

Editeur: American Society of Clinical Oncology

Type: Article scientifique dans une revue à comité de lecture

Année: 2014

Langue: Anglais

Date: 2014/07/07

Titre de la revue: Journal of Clinical Oncology

ISSN: 1527-7755

Résumé en anglais: Purpose This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). Patients and Methods A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age, sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study. Results Of total patients, 3,051 (15%) were age ≤ 50 years. Age was prognostic for both OS (P < .001) and PFS (P < .001), with U-shaped risk (ie, highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted for PS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status. Conclusion Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.

URL de la notice: http://okina.univ-angers.fr/publications/ua9217 [12]

DOI: 10.1200/JCO.2013.54.9329 [13]
Liens

Publié sur Okina (http://okina.univ-angers.fr)